BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that Anika and Galderma Pharma S.A. and Galderma S.A. (together, “Galderma”) have closed on their agreement to terminate all license, development and supply arrangements among the companies for the ELEVESS family of products. Anika has now reacquired the worldwide rights to the future development and marketing of ELEVESS, including ownership of the “ELEVESS” trademark, and all related packaging, marketing and promotional materials, as well as the clinical studies, marketing research and training materials developed by Galderma.
